Limits...
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.

Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, Wang D - Drug Des Devel Ther (2015)

Bottom Line: The correlation of PD-L1 and APE1 expression with the clinicopathologic features of gastric carcinoma was analyzed by SPSS version 19.0.PD-L1 and APE1 positive expressions were significantly associated with depth of invasion, lymph node metastasis, pathological type, overall survival, and higher T stage.Multivariate analysis showed that the depth of invasion was a significant prognostic factor (risk ratio 19.91; P=0.000), but there was no significant relationship with PD-L1, APE1, prognosis, and other characteristics.

View Article: PubMed Central - PubMed

Affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, People's Republic of China.

ABSTRACT

Introduction: Gastric cancer is a fatal malignancy with a rising incidence rate. Effective methods for early diagnosis, monitoring metastasis, and prognosis are currently unavailable for gastric cancer. In this study, we examined the association of programmed death ligand-1 (PD-L1) and apurinic/apyrimidinic endonuclease 1 (APE1) expression with the prognosis of gastric cancer.

Methods: The expressions of PD-L1 and APE1 were detected by immunohistochemistry in 107 cases of human gastric carcinoma. The correlation of PD-L1 and APE1 expression with the clinicopathologic features of gastric carcinoma was analyzed by SPSS version 19.0.

Results: The positive expression rates of PD-L1 and APE1 in gastric cancer tissues were 50.5% (54/107) and 86.9% (93/107), respectively. PD-L1 and APE1 positive expressions were significantly associated with depth of invasion, lymph node metastasis, pathological type, overall survival, and higher T stage. Furthermore, the expression of PD-L1 in highly differentiated gastric cancers was higher than that in poorly differentiated cancers (P=0.008). Moreover, the expression of APE1 and PD-L1 in gastric cancers was positively correlated (r=0.336, P<0.01). Multivariate analysis showed that the depth of invasion was a significant prognostic factor (risk ratio 19.91; P=0.000), but there was no significant relationship with PD-L1, APE1, prognosis, and other characteristics.

Conclusion: The deregulation of PD-L1 and APE1 might contribute to the development and the poor prognosis of gastric cancer. Our findings suggest that high expression of PD-L1 and APE1 is a risk factor of gastric cancer and a new biomarker to predict the prognosis of gastric cancer. Furthermore, our findings suggest that targeting the PD-L1 and APE1 signaling pathways may be a new strategy for cancer immune therapy and targeted therapy for gastric cancer, especially in patients with deep invasion and lymph node metastasis.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier analysis of the relationship between APE1 immunostaining and survival time.Notes: Survival time after surgery in APE1-positive and APE1-negative gastric cancer patients. The median survival time was 29.0 months (P<0.05). APE1 expression is upregulated in gastric cancer and is a marker of poor prognosis in patients with gastric cancer.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4338255&req=5

f3-dddt-9-901: Kaplan–Meier analysis of the relationship between APE1 immunostaining and survival time.Notes: Survival time after surgery in APE1-positive and APE1-negative gastric cancer patients. The median survival time was 29.0 months (P<0.05). APE1 expression is upregulated in gastric cancer and is a marker of poor prognosis in patients with gastric cancer.

Mentions: There was weak or no apparent expression of APE1 in normal tissues adjacent to the carcinoma. However, expression of APE1 could be observed in the nucleus and cytoplasm of gastric cancer cells (Figure 1). About 86.9% (93/107) of gastric carcinoma tissues showed positive APE1 immunostaining. Moreover, APE1 expression in gastric cancer cells was significantly correlated to lymph node metastasis (OR =3.26; P=0.037), depth of invasion (OR =7.61; P=0.001), and survival time (OR =10.91; P=0.040) (P<0.05). There was no significant association of APE1 expression with age, sex, or tumor size of patients (Table 1) (P>0.05). Kaplan–Meier analysis demonstrated that APE1 positive expression was a marker of poor prognosis in gastric cancer patients (P=0.035) (Figure 3). These results show that APE1 expression is upregulated in gastric cancer and is a marker of poor prognosis in patients with gastric cancer.


Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.

Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, Wang D - Drug Des Devel Ther (2015)

Kaplan–Meier analysis of the relationship between APE1 immunostaining and survival time.Notes: Survival time after surgery in APE1-positive and APE1-negative gastric cancer patients. The median survival time was 29.0 months (P<0.05). APE1 expression is upregulated in gastric cancer and is a marker of poor prognosis in patients with gastric cancer.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4338255&req=5

f3-dddt-9-901: Kaplan–Meier analysis of the relationship between APE1 immunostaining and survival time.Notes: Survival time after surgery in APE1-positive and APE1-negative gastric cancer patients. The median survival time was 29.0 months (P<0.05). APE1 expression is upregulated in gastric cancer and is a marker of poor prognosis in patients with gastric cancer.
Mentions: There was weak or no apparent expression of APE1 in normal tissues adjacent to the carcinoma. However, expression of APE1 could be observed in the nucleus and cytoplasm of gastric cancer cells (Figure 1). About 86.9% (93/107) of gastric carcinoma tissues showed positive APE1 immunostaining. Moreover, APE1 expression in gastric cancer cells was significantly correlated to lymph node metastasis (OR =3.26; P=0.037), depth of invasion (OR =7.61; P=0.001), and survival time (OR =10.91; P=0.040) (P<0.05). There was no significant association of APE1 expression with age, sex, or tumor size of patients (Table 1) (P>0.05). Kaplan–Meier analysis demonstrated that APE1 positive expression was a marker of poor prognosis in gastric cancer patients (P=0.035) (Figure 3). These results show that APE1 expression is upregulated in gastric cancer and is a marker of poor prognosis in patients with gastric cancer.

Bottom Line: The correlation of PD-L1 and APE1 expression with the clinicopathologic features of gastric carcinoma was analyzed by SPSS version 19.0.PD-L1 and APE1 positive expressions were significantly associated with depth of invasion, lymph node metastasis, pathological type, overall survival, and higher T stage.Multivariate analysis showed that the depth of invasion was a significant prognostic factor (risk ratio 19.91; P=0.000), but there was no significant relationship with PD-L1, APE1, prognosis, and other characteristics.

View Article: PubMed Central - PubMed

Affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, People's Republic of China.

ABSTRACT

Introduction: Gastric cancer is a fatal malignancy with a rising incidence rate. Effective methods for early diagnosis, monitoring metastasis, and prognosis are currently unavailable for gastric cancer. In this study, we examined the association of programmed death ligand-1 (PD-L1) and apurinic/apyrimidinic endonuclease 1 (APE1) expression with the prognosis of gastric cancer.

Methods: The expressions of PD-L1 and APE1 were detected by immunohistochemistry in 107 cases of human gastric carcinoma. The correlation of PD-L1 and APE1 expression with the clinicopathologic features of gastric carcinoma was analyzed by SPSS version 19.0.

Results: The positive expression rates of PD-L1 and APE1 in gastric cancer tissues were 50.5% (54/107) and 86.9% (93/107), respectively. PD-L1 and APE1 positive expressions were significantly associated with depth of invasion, lymph node metastasis, pathological type, overall survival, and higher T stage. Furthermore, the expression of PD-L1 in highly differentiated gastric cancers was higher than that in poorly differentiated cancers (P=0.008). Moreover, the expression of APE1 and PD-L1 in gastric cancers was positively correlated (r=0.336, P<0.01). Multivariate analysis showed that the depth of invasion was a significant prognostic factor (risk ratio 19.91; P=0.000), but there was no significant relationship with PD-L1, APE1, prognosis, and other characteristics.

Conclusion: The deregulation of PD-L1 and APE1 might contribute to the development and the poor prognosis of gastric cancer. Our findings suggest that high expression of PD-L1 and APE1 is a risk factor of gastric cancer and a new biomarker to predict the prognosis of gastric cancer. Furthermore, our findings suggest that targeting the PD-L1 and APE1 signaling pathways may be a new strategy for cancer immune therapy and targeted therapy for gastric cancer, especially in patients with deep invasion and lymph node metastasis.

No MeSH data available.


Related in: MedlinePlus